Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

RENEGADE: Radioembolization for Early Stage Renal Cell Carcinoma: An Open-Label, Prospective, Multi-Center, Phase 1/2 Safety Trial

NCT06432036 is registered in ClinicalTrials.gov with Jonsson Comprehensive Cancer Center as lead sponsor.

NCT NCT06432036
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06432036 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
RENEGADE: Radioembolization for Early Stage Renal Cell Carcinoma: An Open-Label, Prospective, Multi-Center, Phase 1/2 Safety Trial
Lead sponsor
Jonsson Comprehensive Cancer Center
Phase
Phase 1/2
Overall status
Recruiting
Start date
December 26, 2024
Completion date
March 31, 2030
Enrollment
25 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

stage i renal cell cancer, stage ii renal cell cancer